Durect corp

Financial Times Close.

DURECT harnesses epigenetic modulation to treat serious and life-threatening conditions, including acute organ injury and cancer. Many types of acute organ injuries and cancers are associated with dysregulation of the epigenome, such as DNA methylation. There is vast potential for epigenetic therapies to address the underlying pathophysiology by mitigating epigenomic dysregulation and helping to improve cellular function or suppress tumor growth. Join our highly experienced, talented, and collaborative team as we strive to improve the course of human medicine with novel epigenetic therapies. Brown, President and Chief.

Durect corp

.

Epigenetic Modulation. It allows the website owner to implement or change the website's content in real-time.

.

The pre-funded warrants and the accompanying warrants will be immediately exercisable. The pre-funded warrants do not expire and the accompanying warrants will expire five years from the date of issuance. The closing of the Offering is expected to occur on or about February 8, , subject to customary closing conditions. DURECT intends to use the net proceeds of the Offering for general corporate purposes, which may include clinical trials, research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion, and to meet working capital needs. The Offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating to, and describing the terms of, the Offering will be filed with the SEC.

Durect corp

DURECT harnesses epigenetic modulation to treat serious and life-threatening conditions, including acute organ injury and cancer. Many types of acute organ injuries and cancers are associated with dysregulation of the epigenome, such as DNA methylation. There is vast potential for epigenetic therapies to address the underlying pathophysiology by mitigating epigenomic dysregulation and helping to improve cellular function or suppress tumor growth.

Ben manenti stats

Join our highly experienced, talented, and collaborative team as we strive to improve the course of human medicine with novel epigenetic therapies. Press Releases. J Cardiovasc Aging. The cookie is used to store the user consent for the cookies in the category "Other. All rights reserved. These cookies will be stored in your browser only with your consent. Average volume The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors. Show more Opinion link Opinion. Advertisement advertisement. Necessary Necessary. Used by Motomo Analytics to store a few details about the user such as the unique visitor ID.

Compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days. Numerical improvement in primary endpoint of mortality or transplant at 90 days did not achieve statistical significance.

Explore the Power of Epigenetic Therapy. These cookies track visitors across websites and collect information to provide customized ads. Show more Tech link Tech. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making or refraining from making any specific investment or other decisions. Functional functional. Alcohol-Associated Hepatitis AH. Discover Larsucosterol. All rights reserved. All content on FT. Cancel Continue.